{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Adult+Acute+Myeloid+Leukemia&page=12", "query": { "condition": "Refractory Adult Acute Myeloid Leukemia", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 516, "total_pages": 52, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Adult+Acute+Myeloid+Leukemia&page=13&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Adult+Acute+Myeloid+Leukemia&page=11&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T15:15:22.772Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00245037", "title": "Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Precancerous Condition" ], "interventions": [ { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "Total Body Irradiation (TBI)", "type": "RADIATION" }, { "name": "Granulocyte colony-stimulating factor (G-CSF)", "type": "DRUG" }, { "name": "Phenytoin", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 147, "start_date": "2005-06", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2017-09-27", "last_synced_at": "2026-10-14T15:15:22.772Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00245037" }, { "nct_id": "NCT00602225", "title": "Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Promyelocytic Leukemia (M3)", "Recurrent Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "clofarabine", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "filgrastim", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 50, "start_date": "2007-12", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2018-03-09", "last_synced_at": "2026-10-14T15:15:22.772Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00602225" }, { "nct_id": "NCT07717164", "title": "PRAISE-IR Versus CIBMTR Controls", "overall_status": "NOT_YET_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "ALL (Acute B-Lymphoblastic Leukemia)", "AML (Acute Myeloid Leukemia)", "MDS (Myelodysplastic Syndrome)" ], "interventions": [], "intervention_types": [], "sponsor": "Miltenyi Biomedicine GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "66 Years", "sex": "ALL", "summary": "1 Year to 66 Years" }, "enrollment_count": 51, "start_date": "2026-07-31", "completion_date": "2026-09-30", "has_results": false, "last_update_posted_date": "2026-07-28", "last_synced_at": "2026-10-14T15:15:22.772Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07717164" }, { "nct_id": "NCT04029688", "title": "A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia (AML)", "Acute Lymphoblastic Leukemia (ALL)", "Neuroblastoma", "Solid Tumors" ], "interventions": [ { "name": "Idasanutlin", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Intrathecal Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "0 Years to 30 Years" }, "enrollment_count": 38, "start_date": "2020-01-27", "completion_date": "2024-05-06", "has_results": true, "last_update_posted_date": "2024-12-20", "last_synced_at": "2026-10-14T15:15:22.772Z", "location_count": 5, "location_summary": "Little Rock, Arkansas • Palo Alto, California • Orlando, Florida + 2 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Palo Alto", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04029688" }, { "nct_id": "NCT00006379", "title": "Non-Ablative Allo HSCT For Hematologic Malignancies or SAA", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases", "Precancerous/Nonmalignant Condition", "Small Intestine Cancer" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "graft-versus-tumor induction therapy", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "70 Years", "sex": "ALL", "summary": "Up to 70 Years" }, "enrollment_count": 58, "start_date": "2000-06", "completion_date": "2011-10", "has_results": false, "last_update_posted_date": "2011-12-08", "last_synced_at": "2026-10-14T15:15:22.772Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006379" }, { "nct_id": "NCT00004061", "title": "Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma", "Oral Complications" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "palifermin", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 111, "start_date": "1999-05", "completion_date": "2009-12", "has_results": false, "last_update_posted_date": "2013-06-26", "last_synced_at": "2026-10-14T15:15:22.772Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004061" }, { "nct_id": "NCT01101880", "title": "Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Chronic Myelomonocytic Leukemia", "de Novo Myelodysplastic Syndromes", "Refractory Anemia With Excess Blasts", "Untreated Adult Acute Myeloid Leukemia", "Myeloproliferative Neoplasm With 10% Blasts or Higher" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "clofarabine", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 50, "start_date": "2010-08", "completion_date": "2017-07", "has_results": true, "last_update_posted_date": "2017-10-19", "last_synced_at": "2026-10-14T15:15:22.772Z", "location_count": 3, "location_summary": "Duarte, California • Stanford, California • Seattle, Washington", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01101880" }, { "nct_id": "NCT02323113", "title": "Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myelogenous Leukemia" ], "interventions": [ { "name": "TAK-659", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Calithera Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2015-03-09", "completion_date": "2018-08-15", "has_results": true, "last_update_posted_date": "2023-02-08", "last_synced_at": "2026-10-14T15:15:22.772Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Chicago, Illinois • Niles, Illinois + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Niles", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02323113" }, { "nct_id": "NCT03793478", "title": "Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Quizartinib", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Intrathecal (IT) triple chemotherapy prophylaxis", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Month to 21 Years" }, "enrollment_count": 65, "start_date": "2018-08-15", "completion_date": "2027-05-01", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-10-14T15:15:22.772Z", "location_count": 11, "location_summary": "Loma Linda, California • San Francisco, California • Aurora, Colorado + 8 more", "locations": [ { "city": "Loma Linda", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Wilmington", "state": "Delaware" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03793478" }, { "nct_id": "NCT02484391", "title": "CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Granulocytic Sarcoma", "Recurrent Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "6,8-Bis(benzylthio)octanoic Acid", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Hematopoietic Cell Transplantation", "type": "PROCEDURE" }, { "name": "Mitoxantrone Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2015-09", "completion_date": "2022-02-02", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-10-14T15:15:22.772Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02484391" } ] }